MKTP delivers long-term repigmentation in vitiligo, other leukodermas
Melanocyte-keratinocyte transplantation procedure (MKTP) confers satisfactory long-term repigmentation in patients with leukoderma, with repigmentation lasting for at least 72 months, reports a recent study.
Researchers conducted a retrospective review of electronic medical records for all MKTPs performed at Henry Ford Hospital between January 2009 and April 2014 to assess long-term repigmentation of MKTP in vitiligo and other leukodermas. A 5-point grading scale (poor to excellent) and Vitiligo Area Scoring Index (VASI) were utilized to evaluate repigmentation.
MKTP was performed at 236 anatomically based lesions (ABLs) in a total of 100 patients, of which 63 with 157 ABLs had available long-term data (12 to 72 months; median 24 months).
VASI scores improved in segmental vitiligo (‒75.6±24.6 percent), nonsegmental vitiligo (‒59.2±36.6 percent) and physical leukoderma (‒32.4±33.5 percent). In vitiligo, 53 percent of ABLs maintained >75 percent repigmentation at 24 months after MKTP, 64 percent at 48 months and 53 percent at 72 months.
Age, skin photoype and anatomic location of ABLs did not show any significant impact on the outcome of treatment.
These results support a previous study, which found MKTP to be effective and well-tolerated based upon categorical and VASI assessments of repigmentation. [J Am Acad Dermatol 2012;66:785-93]
The current study is limited by the retrospective design with uncontrolled, postoperative adjuvant treatments and inconsistent compliance to scheduled follow-up evaluations, according to researchers, adding that persistence of pigmentation after MKTP is a critical consideration for efficacy.